83% of the company's portfolio, related to health, hygiene and value for money, delivered 17% sales growth during the quarter. HI category posted mere 4% growth, was a negative surprise, especially considering 22% growth reported by Jyothy Lab in the same segment. We have upward revised our FY21E and FY22E EPS at Rs 17.1 and Rs 18.3, respectively and introduced FY23E EPS estimate at Rs 19.6. We believe that the recent correction in the price makes the stock attractive at CMP. Valuing GCPL at 38x FY23E earnings to arrive at a TP...